Article information
Article
These are the options to access the full texts of the publication Cirugía Española (English Edition)
Subscriber
Purchase
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
References
[1]
J.R. Siewert, A.H. Hölscher, K. Becker, W. Gössner.
Kardiacarcinom: Versuch einer therapeutisch relevanten Klassifikation [Cardia cancer: attempt at a therapeutically relevant classification].
Chirurg, 58 (1987), pp. 25-32
[2]
M. Nakauchi, H.S. Walch, S. Nussenzweig, et al.
Genomic landscape of adenocarcinomas across the gastroesophageal Junction: moving on from the Siewert classification.
Ann Surg, 281 (2025), pp. 989-996
[3]
V. Munitiz, A. Ortiz, D. Ruiz de Angulo, F.L. Martinez de Haro, P. Parrilla.
Results of the different surgical options for the treatment of cancer of the esophagogastric junction: review of the evidence.
Cir Esp (Engl Ed), 97 (2019), pp. 445-450
[4]
M. Bruna Esteban, M.Á Ortíz Escandell, P. Parilla Paricio.
Cancer of the esophagogastric junction: a border in continuous movement.
Cir Esp (Engl Ed), 97 (2019), pp. 425-426
[5]
X. Li, S. Gong, T. Lu, et al.
Proximal gastrectomy versus total gastrectomy for siewert II/III adenocarcinoma of the gastroesophageal Junction: a systematic review and meta-analysis.
J Gastrointest Surg, 26 (2022), pp. 1321-1335
[6]
S. Blank, T. Schmidt, P. Heger, et al.
Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?.
Gastric Cancer, 21 (2018), pp. 303-314
[7]
S. Agarwal, M.G. Bell, L. Dhaliwal, et al.
Population based time trends in the epidemiology and mortality of gastroesophageal Junction and esophageal adenocarcinoma.
Dig Dis Sci, 69 (2024), pp. 246-253
[8]
K. Matsuno, R. Ishihara, M. Ohmori, et al.
Time trends in the incidence of esophageal adenocarcinoma, gastric adenocarcinoma, and superficial esophagogastric junction adenocarcinoma.
J Gastroenterol, 54 (2019), pp. 784-791
[9]
A. Tang, D. Sohal, M. McNamara, S.C. Murthy, S. Raja.
Siewert III adenocarcinoma: still searching for the right treatment combination.
Surg Oncol Clin N Am, 29 (2020), pp. 647-653
[10]
A. Di Leo, A. Zanoni.
Siewert III adenocarcinoma: treatment update.
Updates Surg, 69 (2017), pp. 319-325
[11]
D. Ruiz de Angulo Martín.
The art of making decisions in surgical oncology.
Cir Esp (Engl Ed), 101 (2023), pp. 503-504
[12]
V. Von Hacker.
Uber oesophagoplastik in allgemeinen und über den ersatz der speiseröhre durch antethorakle haut-dickdarmschlauchbildung im besonderen.
Arch Klin Chir, 105 (1914), pp. 973-1018
[13]
V. Reslinger, H. Tranchart, E. D’Annunzio, et al.
Esophageal reconstruction by colon interposition after esophagectomy for cancer analysis of current indications, operative outcomes, and long-term survival.
J Surg Oncol, 113 (2016), pp. 159-164
[14]
M.V. Sanchez, E.T. Alicuben, J.D. Luketich, I.S. Sarkaria.
Colon interposition for esophageal cancer.
Thorac Surg Clin, 32 (2022), pp. 511-527
[15]
J. Wang, Y. Liang, A. Xue, et al.
Intratumoral CXCL13+ CD160+ CD8+ T cells promote the formation of tertiary lymphoid structures to enhance the efficacy of immunotherapy in advanced gastric cancer.
J Immunother Cancer, 12 (2024),
